Please login to the form below

Not currently logged in
Email:
Password:

Kaletra price cut for Brazilian government

US-based pharmaceutical company Abbott has reduced the price of its anti-retroviral (ARV) treatment Kaletra (lopinavir/ritonavir) paid by the government by some 29.5 per cent in 2007 to USD 0.73

US-based pharmaceutical company Abbott has reduced the price of its anti-retroviral (ARV) treatment Kaletra (lopinavir/ritonavir) paid by the government by some 29.5 per cent in 2007 to USD 0.73.

Jose Gomes Temporao, Brazil's health minister, confirmed that the price will fall to USD 0.68 in 2008. The country is expected to save USD 11.4m from the revised pricing scheme and the cost of the drug per patient should drop to around USD 1,000 annually.

Kaletra prescriptions in Brazil number approximately 32,000 under the government's free AIDS programme. Merck's Sustiva (efavirenz) comes a close second in terms of annual costs.

Abbott's cooperation with Brazil came about when the government there threatened to compulsorily license Abbott's drug in 2005, although a compromise price was later settled.

Both Abbott and Merck have created specific pricing models for their ARV drugs in developing countries, but the Brazilian government has only accepted the former's model. Bristol-Myers Squibb (BMS) recently agreed a new pricing system there.

Brazil and Thailand have both intimated that they might extend their compulsory licensing policy to drugs other than ARVs. Bloomberg analysts have said that the government will negotiate cancer medicine prices with Swiss pharmaceutical company ovartis, regarding Gleevec (imatinib), which was recently at the centre of patent disputes in India.

11th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics